KR850001902A - 피페리딘 유도체의 제법 - Google Patents

피페리딘 유도체의 제법 Download PDF

Info

Publication number
KR850001902A
KR850001902A KR1019840004629A KR840004629A KR850001902A KR 850001902 A KR850001902 A KR 850001902A KR 1019840004629 A KR1019840004629 A KR 1019840004629A KR 840004629 A KR840004629 A KR 840004629A KR 850001902 A KR850001902 A KR 850001902A
Authority
KR
South Korea
Prior art keywords
group
compound
formula
hydrogen
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019840004629A
Other languages
English (en)
Other versions
KR910009937B1 (ko
Inventor
마누엘 프리에또 쏘또( 외 3) 호세
Original Assignee
원본미기재
포르도날 에스 에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10546879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR850001902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 포르도날 에스 에이 filed Critical 원본미기재
Publication of KR850001902A publication Critical patent/KR850001902A/ko
Application granted granted Critical
Publication of KR910009937B1 publication Critical patent/KR910009937B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

피페리딘 유도체의 제법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. (a) 하기 구조식(Ⅳ)의 할라이드를 하기 구조식(Ⅴ)의 N－치환－4－하이드록시피페리딘과 반응시키거나 (b) 하기구조식(Ⅷ)의 페닐메톡시피페리딘을 하기구조식(Ⅶ)의 할라이드와 반응시킨다음, R6가 COOH인 구조식(Ⅰ)의 화합물을 원할경우 우선 상기(a) 또는 (b)에 의해 R6가 알콕시카보닐기인 구조식(Ⅰ)의 화합물을 제조한 다음 알콕시카보닐기를 가수분해시켜 하기구조식(Ⅰ)의 화합물을 제조하는 것을 특징으로 하는 피페리딘 화합물의 제조방법.
    상기식들에서, R1은 티에닐기 또는 할로겐원자(바람직하게는 불소, 염소), 저급알콕시 또는 저급알킬기에 의해 임의로 치환된 페닐기를 나타내며 R2는 수소 또는 할로겐(바람직하게는 불소)원자나 저급 알콕시 또는 저급 알킬기를 나타내며, R2는 수소 또는 할로겐(바람직하게는 불소)원자나 저급알킬티오, 저급알콕시, 또는 저급알킬이나 C5또는 C6사이클로알킬기 또는 하기 일반구조(Ⅱ)의 기를 나타내며
    (여기서 R4와 R5는 각기 수소원자 또는 저급알킬기를 나타내며 R6는 사이클로알킬, 하이드록시메틸, 카복시 또는 저급알콕시카보닐기를 나타낸다) W는 카보닐(즉), 하이드록시메틸렌(즉 －CH(OH)－)기를 나타내며, X는 Cl 또는 Br이며, R3는 수소 또는 할로겐원자나 저급알킬티오, 저급알콕시 또는 저급알킬기 또는 C5또는 C6사이클로알킬기이거나 또는 R4와 R5가 상기한 바와 같으며 R6가 사이클로알킬 또는 저급알콕시카보닐기를 나타내는 상기 일반구조(Ⅱ)의 기를 나타낸다.
  2. 하기구조식(ⅩⅣ)인 화합물의 카복시 또는 알콕시카보닐기를 환원시킨다음 보호케탈기를 산 가수분해에 의해 제거하는 것으로 구성된 하기구조식(Ⅰ)의 화합물의 제조방법.
    상기 구조식들에서, R1과R2,는 상기한 바와 같으며, W는 카보닐기이며,R3는 R4와 R5가 상기한 바와 같으며 R6가 하이드록시메틸인 구조(Ⅱ)의 기이며; R8는 수소 또는 알킬기이다.
  3. 하기구조식(ⅩⅦ)의 화합물에서 케탈기를 산가수분해하여 제거하는 것으로 구성된 하기구조식(Ⅰ)의 화합물의 제조방법.
    상기식들에서, R1,R2는 상기 정의한 바와 같으며, W는 카보닐기이며, R3″는 수소, 또는 할로겐, 저급알킬티오, 저급알콕시, 저급알킬기 또는 C5또는 C6사이클로알킬기이다.
  4. 하기 구조식(ⅩⅧ)인 화합물의 카복시 또는 알콕시카보닐기를 환원시키거나 하기구조식(ⅩⅨ)인 화합물의 카보닐기와 카복시 또는 알콕시카보닐기를 환원시키는 것으로 구성된 하기구조식(Ⅰ)의 화합물의 제조방법.
    상기식들에서 R1,R2는 상기 정의한 바와 같으며 W는 하이드록시메틸렌기이며, R3는 R4와 R5와 상기한 바와 같으며 R6가 하이드록시메틸기인 상기구조식(Ⅱ)의 기이며; R8은 H 또는 알킬이다.
  5. 제1항 내지4항중 어느 하나에서 R2이페닐, 플루오로페닐, 메틸페닐, 메톡시페닐 또는 티에닐기인 방법.
  6. 제1항 내지 5항중 어느 하나에서 R2가 H,F Cl, CH3또는 CH3O인 방법.
  7. 제1항 내지 6항중 어느 하나에서 R3가 H,F, Br, 에틸, 이소프로필, t－부틸, 메톡시 또는 사이클로헥실인 방법.
  8. 제1항 내지 7항중 어느 하나에서 R3가이며 여기서 R4와 R5가 H 또는 메틸이고 R6가 사이클로프로필, 에톡시카보닐, 카복시 또는 하이드록시메틸인 방법.
  9. 제1항 내지 4항중 어느 하나에서 4－디페닐메톡시－α－(4－t－부틸페닐)－1－피페리딘부탄올, 4－디－(4－플루오로페닐) 메톡시－1－[3－(4－t－부틸벤조일)프로필]－피페리딘, 4－α－[2－티에닐)－벤질옥시]－1－[3－(4－t－부틸벤조일)프로필]－피페리딘, 4－디페닐－메톡시－α－(4－사이클로헥실페닐)－1－피페리딘부탄올 또는 4－디페닐－메톡시－1－[3－(4－이소프로필 벤조일)－프로필]－피페리딘 및 그의 산부가염을 제조하는 방법.
  10. 제1항 내지 4항중 어느 한항에서 4－디페닐메톡시－1－[3－(4－t－부틸벤조일)프로필]－피페리딘과 그의 산부가염을 제조하는 방법.
  11. 제1항 내지 10항중 어느 하나에서 화합물을 제약상 허용되는 산과 반응시켜 염으로 전환시키는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것
KR1019840004629A 1983-08-05 1984-08-03 피페리딘 유도체 및 그의 제법 Expired KR910009937B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8321157 1983-08-05
GB838321157A GB8321157D0 (en) 1983-08-05 1983-08-05 Piperidine derivatives

Publications (2)

Publication Number Publication Date
KR850001902A true KR850001902A (ko) 1985-04-10
KR910009937B1 KR910009937B1 (ko) 1991-12-06

Family

ID=10546879

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840004629A Expired KR910009937B1 (ko) 1983-08-05 1984-08-03 피페리딘 유도체 및 그의 제법

Country Status (22)

Country Link
US (1) US4550116A (ko)
EP (1) EP0134124B1 (ko)
JP (1) JPS6094962A (ko)
KR (1) KR910009937B1 (ko)
AT (1) ATE30418T1 (ko)
AU (1) AU565293B2 (ko)
CA (1) CA1264324A (ko)
DE (2) DE3466982D1 (ko)
DK (1) DK158348C (ko)
EG (1) EG16936A (ko)
ES (5) ES8505980A1 (ko)
FI (1) FI81567C (ko)
GB (1) GB8321157D0 (ko)
GR (1) GR80031B (ko)
HU (1) HU196370B (ko)
IL (1) IL72465A (ko)
MX (2) MX156547A (ko)
MY (1) MY101017A (ko)
NZ (1) NZ209023A (ko)
PH (1) PH19880A (ko)
PT (1) PT79028B (ko)
ZA (1) ZA845968B (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPS625956A (ja) * 1985-07-02 1987-01-12 Terumo Corp ビニル誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same
US5231104A (en) * 1988-07-08 1993-07-27 Pfizer Inc. 1-arylethyl-3-substituted piperidines
CA2015949A1 (en) * 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
FR2655649B1 (fr) * 1989-12-12 1994-07-08 Adir Nouveaux derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4034218A1 (de) * 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
JP2624372B2 (ja) * 1990-11-15 1997-06-25 宇部興産株式会社 ジアリールメトキシピペリジン誘導体
FR2673842B1 (fr) * 1991-03-13 1993-12-24 Rhone Poulenc Rorer Sa Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4.
US5190959A (en) * 1991-08-08 1993-03-02 Kaken Pharmaceutical Co. Ltd. Piperidine compounds which have useful pharmaceutical activity
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
EP0703902B1 (en) * 1993-06-24 1998-12-16 Albany Molecular Research, Inc. Process for the production of piperidine derivatives
US20020007068A1 (en) * 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
JP3712208B2 (ja) * 1993-06-25 2005-11-02 メレルファーマスーティカルズ インコーポレイテッド 抗ヒスタミン性の４−ジフェニルメチル／ジフェニルメトキシピペリジン誘導体類を製造する新規な中間体
MX9701305A (es) 1994-08-25 1998-05-31 Merrell Pharma Inc Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
KR19990008406A (ko) * 1995-05-08 1999-01-25 스티븐엘.네스비트 알파-(치환된 알킬페닐)-4-(히드록시디페닐메틸)-1-피페리딘 부탄올 유도체들, 그들의 제조 방법 및 항히스타민제, 항알러지제및 기관지 확장제로서 그들의 용도
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6700012B2 (en) 1998-07-02 2004-03-02 Aventis Pharmaceuticals Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6683094B2 (en) 1998-07-02 2004-01-27 Aventis Pharmaceuticals Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7498443B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2231043B2 (es) * 2004-10-29 2005-10-01 Laboratorios Cinfa, S.A. Composicion farmaceutica de ebastina de liberacion inmediata y su proceso de fabricacion.
WO2006080415A1 (ja) * 2005-01-31 2006-08-03 Y's Therapeutics Co., Limited 膀胱障害を治療または予防するための組成物および方法
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
CN100443470C (zh) * 2006-07-21 2008-12-17 杭州保灵有限公司 一种依巴斯汀的制备方法
DE102008000351B4 (de) 2008-02-20 2017-08-10 Aristo Pharma Gmbh Verfahren zur Herstellung eines Ebastin enthaltenden Granulats sowie einer festen pharmazeutischen Zusammensetzung, Ebastin enthaltendes Granulat und dessen Verwendung
WO2009157006A1 (en) 2008-06-26 2009-12-30 Micro Labs Limited Process of preparing ebastine
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
EP2371817A1 (en) 2010-04-01 2011-10-05 Arevipharma GmbH Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof
DE202011000756U1 (de) 2011-03-31 2011-10-12 Micro Labs Limited Ebastine, nicht-mikronisierte Ebastinepartikel und pharmazeutische Zusammensetzungen umfassend Ebastine
WO2013062498A1 (en) * 2011-10-13 2013-05-02 Mahmut Bilgic Solid oral formulations comprising ebastine
WO2013081562A1 (en) 2011-10-13 2013-06-06 Mahmut Bilgic Oral formulations comprising ebastine
ES2606148T3 (es) 2011-11-01 2017-03-22 Inopharm Limited Composición de disgregación oral de agentes antihistamínicos
CN109593058B (zh) * 2019-01-23 2021-09-24 江苏联环药业股份有限公司 一种依巴斯汀的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
EP4247331B1 (en) 2020-11-18 2025-10-08 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound
CN112574097B (zh) * 2020-12-21 2023-01-03 杭州仟源保灵药业有限公司 Ebastine及其富马酸盐的制备方法
CN114014796A (zh) * 2021-11-16 2022-02-08 江苏联环药业股份有限公司 一类依巴斯汀的盐及其制备方法和应用
JP2025514548A (ja) * 2022-05-06 2025-05-02 チォンドウ シーベイカン バイオメディカル テクノロジー カンパニー リミテッド カレバスチンの塩及びその用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB688354A (en) * 1950-04-07 1953-03-04 Nopco Chem Co Improvements relating to compounds of the benzhydryl ether type
US2716122A (en) * 1953-10-19 1955-08-23 Nopco Chem Co N-substituted-4-benzhydryl ether-piperidines
GB895309A (en) * 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3080372A (en) * 1960-03-25 1963-03-05 Res Lab Dr C Janssen 1-aroylalkyl-4-arylpiperidine derivatives
GB963639A (en) * 1960-10-20 1964-07-15 Arnold Heyworth Beckett New piperidine derivatives and processes for preparing the same
BE615410A (ko) * 1961-03-22
DE1645968A1 (de) * 1966-05-09 1972-04-06 Aldrich Chem Co Inc Piperidinderivate und Verfahren zu deren Herstellung
US3446014A (en) * 1968-01-17 1969-05-27 Struthers Energy Systems Inc Pulverizer
US3679666A (en) * 1969-04-03 1972-07-25 Hoffmann La Roche 4-(4-hydroxypiperidino)-4'-fluorobutyrophenones
US3799932A (en) * 1970-03-20 1974-03-26 Sumitomo Chemical Co Gamma-piperidinobutyrophenones
US3743645A (en) * 1970-10-19 1973-07-03 Robins Co Inc A H 1-substituted-4-phenoxypiperidines
US4070473A (en) * 1973-01-26 1978-01-24 Ab Ferrosan Piperidino-butyrophenones
FI60559C (fi) * 1975-07-17 1982-02-10 Sumitomo Chemical Co Foerfarande foer framstaellning av ny-(tertiaer amino)-orto-aminobutyrofenonfoereningar
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
US4312876A (en) * 1979-02-23 1982-01-26 Hoechst-Roussel Pharmaceuticals Incorporated Antidepressive and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
US4424357A (en) * 1979-02-23 1984-01-03 Hoechst-Roussel Pharmaceuticals, Inc. Process for preparing 4-aryloxy-3-phenylpiperidines
FR2450816A1 (fr) * 1979-03-09 1980-10-03 Metabio Joullie Sa Nouveaux derives de la piperidine, leur procede de preparation et leur application en therapeutique
IE49998B1 (en) * 1979-08-06 1986-01-22 Merrell Dow Pharma 4-(naphthalenyloxy)piperidine derivatives
ATE13425T1 (de) * 1981-10-15 1985-06-15 Synthelabo Piperidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.

Also Published As

Publication number Publication date
DK378784D0 (da) 1984-08-03
ES534436A0 (es) 1985-09-01
ES8507128A1 (es) 1985-09-01
PT79028A (en) 1984-09-01
IL72465A (en) 1988-08-31
ES534435A0 (es) 1985-06-16
DK158348B (da) 1990-05-07
MX156547A (es) 1988-09-06
ES534437A0 (es) 1985-07-16
ES8506298A1 (es) 1985-07-16
US4550116A (en) 1985-10-29
ES534439A0 (es) 1985-09-01
KR910009937B1 (ko) 1991-12-06
EP0134124A1 (en) 1985-03-13
AU565293B2 (en) 1987-09-10
DE3466982D1 (en) 1987-12-03
ATE30418T1 (de) 1987-11-15
GR80031B (en) 1984-12-11
ES534438A0 (es) 1985-07-01
ES8505980A1 (es) 1985-07-01
EG16936A (en) 1994-02-28
DE19875026I2 (de) 2002-01-31
MY101017A (en) 1991-06-29
FI81567B (fi) 1990-07-31
DK378784A (da) 1985-02-06
MX9203149A (es) 1992-07-01
FI843053A0 (fi) 1984-08-02
GB8321157D0 (en) 1983-09-07
JPH0432821B2 (ko) 1992-06-01
IL72465A0 (en) 1984-11-30
ES8507127A1 (es) 1985-09-01
HU196370B (en) 1988-11-28
DK158348C (da) 1990-10-08
PT79028B (en) 1986-08-22
PH19880A (en) 1986-08-13
FI81567C (fi) 1990-11-12
ES8505979A1 (es) 1985-06-16
EP0134124B1 (en) 1987-10-28
HUT34446A (en) 1985-03-28
FI843053A7 (fi) 1985-02-06
JPS6094962A (ja) 1985-05-28
CA1264324A (en) 1990-01-09
AU3146584A (en) 1985-02-14
NZ209023A (en) 1988-02-29
ZA845968B (en) 1985-03-27

Similar Documents

Publication Publication Date Title
KR850001902A (ko) 피페리딘 유도체의 제법
KR880012526A (ko) l-페닐-3-나프탈레닐옥시프로판아민
KR830001947A (ko) 화합물의 제조방법
YU66096A (en) Process and intermediates for preparing 1-benzyl-4-((5,6-dimethoxy -1-indanon)-2-yl)methylpiperidine
JPS5762259A (en) Preparation of substituted quinolinecarboxylic acid derivative
JPS559064A (en) Novel stabilizer
KR890013007A (ko) 벤조디옥솔 유도체 및 그의 제조방법
KR850004754A (ko) 3-인돌 카르복사미드 화합물류의 제조방법
KR860006462A (ko) 1,8-나프틸리딘 유도체, 그 에스테르 또는 그 염의 제조방법
KR850001746A (ko) 퀴나졸린 화합물의 제조방법
EP0204309A3 (en) Substituted n-benzyl-4(benzhydryl) piperidines
KR860001045A (ko) 메발로노락톤의 나프틸 동족체의 제조방법
KR900011709A (ko) 신규한 테트랄린 유도체
DE69027084D1 (de) Verfahren zur Herstellung von Purinverbindungen
KR850002988A (ko) 페니실린 유도체의 제조방법
KR860002508A (ko) 푸로(3,2-c)피리딘 유도체, 그의 제법 및 그를 포함하는 의약 조성물
GB1397647A (en) Thiophene derivatives
ATE109140T1 (de) Herstellung von piperidinylcyclopentylheptensäure-derivaten.
KR860003212A (ko) 2-피리딘-티올 유도체 및 그의 산부가염의 제조 방법
KR840006334A (ko) 설파모일 벤조페논 유도체의 제조방법
KR850002093A (ko) 옥타하이드로 인돌리진 프로파노산 및 이와 관련된 화합물의 제조방법
ATE61329T1 (de) Verfahren zur herstellung von rooperol, hypoxosid und deren derivaten.
KR920002509A (ko) 살균제의 중간산물
KR920002594A (ko) 5-이소티아졸아민 유도체
KR850007065A (ko) 포스폰산 디에스테르의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19840803

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19890803

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19840803

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19910513

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19911106

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19920220

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19920413

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19920413

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19941202

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19951204

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19961127

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19970825

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19981120

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19991123

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20001130

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20011128

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20021121

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20031119

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20031119

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term